Reforming Pharmaceutical Industry-Physician Financial Relationships: Lessons from the United States, France, and Japan
David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Journal of Law, Medicine & Ethics 39 (4):662-670 (2011)
This article compares the means that the United States, France, and Japan use to oversee pharmaceutical industry-physician financial relationships. These countries rely on professional and/or industry ethical codes, anti-kickback laws, and fair trade practice laws. They restrict kickbacks the most strictly, allow wide latitude on gifts, and generally permit drug firms to fund professional activities and associations. Consequently, to avoid legal liability, drug firms often replace kickbacks with gifts and grants. The paper concludes by proposing reforms that address problems that persist when firms replace kickbacks with gifts and grants based on the experience of the three countries
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
Marc A. Rodwin (2010). Drug Advertising, Continuing Medical Education, and Physician Prescribing: A Historical Review and Reform Proposal. Journal of Law, Medicine & Ethics 38 (4):807-815.
Citations of this work BETA
Marc A. Rodwin (2013). Five Un‐Easy Pieces of Pharmaceutical Policy Reform. Journal of Law, Medicine & Ethics 41 (3):581-589.
Similar books and articles
Shaili Jain (2007). Understanding Physician-Pharmaceutical Industry Interactions. Cambridge University Press.
Steven C. Schachter (ed.) (2008). Managing Relationships with Industry: A Physician's Compliance Manual. Elsevier.
John T. Fielding (1999). Dangerous Medicine: The Pharmaceutical Industry's Questionable Ethical Practices. Dissertation, Salve Regina University
Richard T. de George (2005). Intellectual Property and Pharmaceutical Drugs. Business Ethics Quarterly 15 (4):549-575.
Jeffrey T. Berger (2003). Pharmaceutical Industry Influences on Physician Prescribing: Gifts, Quasi-Gifts, and Patient-Directed Gifts. American Journal of Bioethics 3 (3):56-57.
Eng Tuck Cheah, Wen Li Chan & Corinne Lin Lin Chieng (2007). The Corporate Social Responsibility of Pharmaceutical Product Recalls: An Empirical Examination of U.S. And U.K. Markets. [REVIEW] Journal of Business Ethics 76 (4):427 - 449.
Jerome P. Kassirer (2005). On the Take: How America's Complicity with Big Business Can Endanger Your Health. Oxford University Press.
Dale Murray & Heather Certain (2007). Pharmaceutical “Gift-Giving,” Medical Education, and Conflict of Interest. Journal of Philosophical Research 32 (Supplement):335-343.
Marc A. Rodwin (2010). Conflicts of Interest and the Future of Medicine: The United States, France, and Japan. Oxford University Press.
David Badcott (2013). Big Pharma: A Former Insider's View. [REVIEW] Medicine, Health Care and Philosophy 16 (2):249-264.
Francesca Marin (2012). Marc A. Rodwin: Conflicts of Interest and the Future of Medicine: The United States, France, and Japan. [REVIEW] Theoretical Medicine and Bioethics 33 (6):443-446.
Marcia M. Boumil, Emily S. Cutrell, Kathleen E. Lowney & Harris A. Berman (2012). Pharmaceutical Speakers' Bureaus, Academic Freedom, and the Management of Promotional Speaking at Academic Medical Centers. Journal of Law, Medicine & Ethics 40 (2):311-325.
Added to index2011-11-16
Total downloads9 ( #254,415 of 1,726,249 )
Recent downloads (6 months)1 ( #369,877 of 1,726,249 )
How can I increase my downloads?